Sharon Townson insider trades: Monte Rosa Therapeutics (GLUE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sharon reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | GLUE | ↓ Sell | 6,000 | $23.31 | $140K | Direct | Jul 7, 2026 (1d) |
| Jun 17, 2026 | GLUE | ↓ Sell | 3,000 | $19.00 | $57K | Direct | Jun 18, 2026 (1d) |
| Jan 5, 2026 | GLUE | ↓ Sell | 3,155 | $15.17 | $48K | Direct | Jan 5, 2026 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other GLUE insiders
Open-market trades in the last 12 months
About Sharon Townson's insider trades
Sharon Townson is Chief Scientific Officer at Monte Rosa Therapeutics (GLUE). Since Jan 5, 2026, Sharon has reported no open-market purchases and 3 sales worth $245K on SEC Form 4. In the last 12 months: 3 sales ($245K).
Their filings also include grants and awards (5 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every GLUE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.